BBL-header-logo

BIG PIcture

Biosimilars saved the European healthcare systems over €30 billion‡ since 20121.

Biocon Biologics is proud to lead the way in the advancement of biosimilars. As we continue to drive innovation and invest in the future, our mission is singularly focused on the development, manufacturing, distribution, and commercialization of high quality biosimilars in the world.

  • ~4.5 billion treatment days provided to European patients since launch1
  • +13% patient treatment days were attributed to biosimilars in 20221*

*2022 over 2021
‡ 2012 – 2022 cumulative savings at list prices from the impact of biosimilar competition in Europe. List prices across Europe act as a base-case to estimate savings generated in European markets.
1. IQVIA, White Paper. The Impact of Biosimilar Competition in Europe. December 2022

BIOCON BIOLOGICS

A fully integrated global biosimilars company, all in on biosimilars.

  • A unique biosimilars portfolio spanning from insulins to recombinant proteins, and monoclonal antibodies
  • Cutting-edge science and research capabilities
  • Experience built from successful global partnership with Mylan/Viatris
  • Global-scale manufacturing with high standards of quality and compliance

20+ biosimilars

approved or in development

8 biosimilars

launched across global markets

100+ countries

where Biocon Biologics’ biosimilars are available

5.7M patients served

globally by Biocon Biologics’ biosimilars

Legacy Of Success

A long-standing presence in the biosimilars industry

Biocon Biologics has emerged as a leading biosimilars player in Europe and worldwide, providing innovative and more affordable ways to treat diabetes, cancer, and autoimmune diseases. As a result of its successful global partnership with Viatris, Biocon Biologics has broadened its biosimilars capability from lab to market, commercializing the products it has been manufacturing for years.

Timeline Slider

Timeline

1978
Founded to improve access to quality bioenzymes
2000
Evolves into biopharmaceuticals
2004
Biocon is the first company worldwide to develop human insulin on a Pichia expression system rh=recombinant human
2009
Partners with Mylan/Viatris to co-develop a biosimilar antibodies portfolio for global markets
2017-21
Solidifies presence in Europe and global biosimilars space
2019
Continues partnership with Viatris after Mylan/Upjohn merger
2023
Biocon Biologics acquires Viatris’ global biosimilars business to become a fully integrated biosimilars company in the US and Europe
1978
Founded to improve access to quality bioenzymes
2000
Evolves into biopharmaceuticals
2004
Biocon develops human insulin on Pichia
2009
Partners with Mylan/Viatris

IMPACT AREAS

Path-breaking
offerings with a focus
on the future.

With a unique portfolio of monoclonal antibodies and insulins, Biocon Biologics is fully committed to the long-term sustainability of global biosimilars access, investing more than $1 billion in R&D and global-scale manufacturing over the last 2 decades.

Biocon Biologics has 20 biosimilar assets in the pipeline, including insulins and monoclonal antibodies spanning therapy areas such as:

DIABETES

ONCOLOGY

IMMUNOLOGY

BONE HEALTH

OPHTHALMOLOGY

Biocon Biologics: an integrated player with proven end-to-end expertise

Research and
Innovation

Product
Development

Clinical
Trials

Global-scale
Manufacturing

Regulatory
Sciences

Commercialization

Our ongoing efforts continue to expand affordable
access to biosimilars for patients worldwide

You are now leaving www.bioconbiologicseu.com, a Biocon Biologics website. The website you are about to access is not owned or controlled by Biocon Biologics. Biocon Biologics assumes no responsibility for and makes no warranties or representation of any kind as to the accuracy, currency, or completeness any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Biologics, and a link to this website from another website does not imply a relationship between Biocon Biologics and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party’s terms and policies (including its privacy policy). Biocon Biologics shall not be liable for any direct, indirect, consequential, incidental or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.

Continue
Cancel